CD276 and glioblastoma: The results obtained showed that patients with GBM with high expression levels of CD276 were resistant to lomustine (Fig. 15E) and nitrosourea (Fig. 15F), whereas no statistical significances were identified with regard to their sensitivity to temozolomide (Fig. 15G).